Chief Executive Officer, North Star Asia
Strong business leadership track record of over 35 years in Health care and FMCG industries in multi countries focusing on sustainable and responsible growth in J&J and GSK. Currently CEO North Star Asia LLP, Management Consultant and Senior Advisor, PAG Holdings Hong Kong. Mr. Vaidheesh was also previously MD and VP (South Asia), GSK. Created new business models and markets, turned around declining businesses, flourished in various leadership situations. Winner of Economics Times award as the “Most Promising Asian Leader of the year -2016”. Won the prestigious Michel Porter award for “Shared value-2016”. President of OPPI 2017-2020. Winner of the prestigious Fair business practices Trophy. Signed and executed MOU with China Communist Party School for health care initiatives for J&J. Honorary Fellow of the Minimal Access Surgeons Association of India.
Managing Partner, SV Health Managers
Kate Bingham, Managing Partner at life sciences venture capital firm SV Health Investors, co-leads SV’s biotech franchise which has a long history of building companies developing transformational new medicines. SV’s investments have resulted in the launch of twenty drugs for inflammatory and autoimmune disease, blindness and cancer.
In 2021 Kate was awarded a DBE in the Queen’s Birthday Honours for her services as Chair of the UK Vaccine Taskforce, where she led a team of world-class experts with the shared purpose of finding and manufacturing COVID-19 vaccines.
Kate is a board member of the Francis Crick Institute and helped launch the Dementia Discovery Fund. She has a first class degree in Biochemistry from the University of Oxford and an MBA from Harvard Business School (Baker Scholar).
Principal, Bishop & Associates
It is with great sadness that we remember Scrip Awards judge, Bill Bishop. In Memoriam
Bishop & Associates is an independent consultancy serving the pharmaceutical, biotechnology, and medical technology sectors. Bishop retired from Becton Dickinson (BD) in 2017. He has served as Chair of Pharma Delegates, Chair of the American Chamber of Commerce Healthcare Committee, and Board Member & Lecturer, Temple University Japan Campus. Bishop has served on Leadership Teams as a Senior Executive for both Eli Lilly & Company and Wyeth Pharmaceuticals (Pfizer) in Japan. His extensive corporate experience included building and managing functions from Government/Industry Relations; Communications; CSR; Issue/Crisis Management; and Advocacy/Stakeholder Management to the core capabilities of Market Access, Pricing, and Reimbursement.
Edison Investment Research
Dr Laura Brown is Course Director of the MSc in Clinical Research, University of Cardiff and a Training and QA Consultant.
Dr Brown has held a number of international and senior management positions in the pharmaceutical industry. She has worked for several international companies including GlaxoWellcome, Hoechst Marion Roussel and Phoenix International.
She was a member of the Editorial board of the Good Clinical Practice Journal for 10 years. She is author of several books including Project Management for the Pharmaceutical Industry, a Practical Guide to the Clinical Trial Directive and several articles on the new EU Clinical Trial Regulation.
Founder, President and Chief Executive Officer, Danssen Consulting
Dr. Ajit Dangi is President & CEO of Danssen Consulting, a strategy firm specialising in Life Sciences and Healthcare. He has served as the Chairman of the Board of Fulford India Ltd., a subsidiary of Merck & Co. Inc. USA for ten years. He is also Director of Atul Bioscience Ltd. India. Dr. Dangi has served as President & Executive Director of Johnson & Johnson India Ltd . where he worked for twenty years in various capacities. He has also served as Director General of Organisation of Pharmaceutical Producers of India (OPPI) for over seven years.
Dr. Dangi is a Graduate in Chemistry from University of Bombay and later earned his Masters and Doctorate ( Ph.D. ) degrees in Pharmaceutical Chemistry from University of London , England . He has also undergone Advanced Management Program from Kellogg Graduate School of Business, Chicago, USA.
Chief Executive Officer & Chairwoman of the Board, Halloran Consulting Group
Laurie Halloran founded Halloran Consulting Group in 1998, originally operating out of an unfinished bathroom. Her time as a pediatric ICU nurse had inspired her to start a company that helps move new therapies through FDA processes to get them into the hands of patients desperately in need. By providing a strategic development team, innovative start-up companies could have access to world-class expertise at a fraction of the cost. Since its humble beginnings, Halloran has grown into a successful consultancy of like-minded experts who are dedicated to improving human health by making life science companies better at what they do.
Laurie has been named 2018 Women’s Business Enterprise Star by the Women's Business Enterprise National Council (WBENC) and has won a 2017 Enterprising Women of the Year Award from Enterprising Women Magazine. Halloran Consulting Group was also named an Inc. 5000 Fastest Growing Company for the past three years in a row. In 2015, Laurie was honored by the Boston Business Journal as a Woman of Influence, in 2010 was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice, and in 2009, she was awarded Clinical Researcher of the Year by the New England Chapter of the Associate of Clinical Research Professionals.
Laurie lectures at Boston University Medical School and the Tufts Center for Drug Development Post-Graduate program. She has previously taught at George Washington University and Harvard University. Laurie earned a Bachelor of Science in Nursing from Russell Sage College and a Master of Science in Management from Lesley University. She is also a Prosci Certified Change Practitioner.
Independent Advisor, former Pharma exec and biotech VC with 3i plc
Director, E-Therapeutics
Jones is chairman of the Oxford-based AI drug discovery company e-Therapeutics and a member of the board of the USA vaccine company Techimmune LLC. He was formerly R&D Director of the Wellcome Foundation, a director of Allergan Inc. and Director General of the Association of the British pharmaceutical industry (ABPI ). He is a visiting professor at Kings College London
Founder, Mehta Partners
Viren founded and is managing member of Mehta Partners, LLC. His analytical insights on global health care have influenced biopharmaceutical strategy and investments worldwide. Educated at the University of Southern California (Doctor of Pharmacy) and UCLA (MBA in international finance and marketing), he has worked with senior BioPharma leaders and investment managers for over 30 years.
Gather Health has been one of Viren’s recent initiatives to empower patients while enhancing physician productivity. Gather Health aims to bring together patient’s providers and patient’s personal network, enabling patient to get real-time and active resources and motivation from this team to improve outcomes.
Viren's biopharma strategic advisory work focuses on refining the business model to expand global healthcare access, and to help the bio-pharmaceutical industry succeed globally. His philanthropic work in ecology and education through viram Foundation includes board role with Project Hope (Washington DC) and the Venice Family Clinic (Los Angeles, CA).
Viren began his career at Merck & Co. in international strategic planning and competitor analysis. This foundation prompted Wood MacKenzie & Company Inc. to invite him to establish a pharmaceutical research function in New York. This effort was expanded at S.G. Warburg & Company, and led to the formation of the BioPharma investment advisory group Mehta and Isaly. Now known as Mehta Partners, with a 30-year record, Viren continues to focus on helping refine investment strategy to achieve global growth while enhancing access to healthcare innovations.
Chairman, Institute of Clinical Research, Director ALM Consultancy
A molecular geneticist by training, Dr. Alison Messom has nearly 20 years of industry experience, working both within Pharmaceutical Companies and Clinical Research Organisations and is the current Chairman of the Board of Directors of the ICR.
With detailed experience of directing global clinical trials, Dr. Messom has worn many different hats during her career. She has had the opportunity to travel far and wide on business; lived in the UK, France and Switzerland, and gained operational experience in over 50 countries and line management in over 30.
During the course of her career she has line managed at all levels from CTAs through to Directors and VPs. At both i3 Research and ICON she helped build a new department of dedicated line managers for CRAs and also Start Up teams. While within the Pharma environment she line managed teams within Study and Project Management, Clinical Supplies, Translational Medicine, Data Management, Statistics, Informatics and IT – showing that line management skills are transferrable across functional areas.
Chairman, Strategic Business Partners
President, Center for Medicine in the Public Interest
Peter Pitts is a Visiting Professor at the University of Paris Medical School and President of the Center for Medicine in the Public Interest. He is a former member of the United States Senior Executive Service and Associate Commissioner of the US Food & Drug Administration. Pitts is a member of the Council for International Organizations of Medical Sciences (CIOMS) Expert Working Group to help advance patient involvement in the development and safe use of medicines. (CIOMS is an international, non-governmental, non-profit organization established jointly by WHO and UNESCO in 1949.) He is the lead author of many professional peer reviewed publications including the Lancet, Therapeutic Innovation and Regulatory Science, and Nature Biotechnology. He is an Associate Editor of Therapeutic Innovation & Regulatory Science (the official DIA journal), a member of the External Advisory Board, IMS Institute for Healthcare Informatics in Asia, Executive Advisory Board, the Galien Foundation, Editorial Advisory Board, Food and Drug Policy Forum, Advisory Board, Journal of Commercial Biotechnology and a member of the Editorial Advisory Board of The Patient Magazine. Pitts lives in New York City.
Specific areas of global policy expertise include FDA policy and process, healthcare technology assessment and reimbursement issues, real world evidence, social media, off label-communications, pharmacovigilance, patient-focused drug development, abuse-deterrent opioids, biosimilar development, Rx-to-OTC switching, risk management plans, GMP policies, pharmacy education programs, drug safety, Critical Path, personalized medicine, clinical trial transparency, IP protection, FDA reform, drug importation, counterfeiting, genetically modified food issues, food safety and security, recalls, nutritional labeling.
Director, Analyst, Edison Investment Research
Smith began his career as a scientist in the research and development division of ICI and then SmithKline Beecham. After completing his PhD in Molecular Biology at the University of Nottingham and Glaxo, and after then an MBA, Smith switched to a commercial role at SB Pharmaceuticals and was appointed global brand manager for Bactroban and new products in Anti-Infectives Strategic Product Development (SPD). In 2000, Smith moved into asset management and venture capital at 3i Group and subsequently held the position of lead fund manager for four life science specific funds – 3i Bioscience Investment Trust PLC, International Biotechnology Trust PLC, and AXA Framlington Biotech Fund. Smith was awarded the Techmark technology fund manager of the year for 2007.
After leaving AXA in 2010, Smith held appointments as director of business development at the Oxfordshire Bioscience Network and head of corporate finance at PharmaVentures. Smith has also taught the life science company valuation, finance and analysis module on the University of Cambridge MPhil program for over ten years. Smith returned to specialist fund management in 2012 to manage the Magna Biopharma Income Fund.
In 2017 Andy moved to the Pricing & Market Access group at ICON in London where he advised big pharma and smaller life science companies on the valuation and commercialisation of their products and returned to the City at the end of 2017 to work at Edison.
Founder, Spiegel Consulting
Editor in Chief, Journal of Generic Medicines
Dr Brian Tempest has held many Non-Executive roles in the Corporate, Educational and NGO Sectors. These positions include Pharmaceuticals, Hospital Management, Medical Diagnostics, Packaging, Financial Services, University Advisory Boards and the United Nations Patent Pool. He is currently Non-Executive Chairman of Touch Medical Media Group Holdings in the UK and is on the Board of a number of international Healthcare Companies as well as advising others from Europe and Asia.
Brian has previously worked for GSK, Pfizer, Sanofi and Sun Pharmaceuticals in leadership positions. He holds FRSC, FRSM, BSc, PhD and DSc qualifications and now resides in Wales, UK.
